Table 5.
Treatment group | RT | FT | FT + ISBS | P α | P β | P γ |
---|---|---|---|---|---|---|
Hb, g/L | 9.3 ± 0.7 | 9.4 ± 0.9 | 11.2 ± 1.1 | NS | <0.05† | <0.05§ |
TBil, μmol/L | 37.5 ± 5.6 | 39.2 ± 7.1 | 38.2 ± 6.5 | NS | NS | NS |
IBil, μmol/L | 27.8 ± 5.1 | 29.8 ± 6.7 | 29.6 ± 7.7 | NS | NS | NS |
AST, U/L | 255.2 ± 99.2 | 249.2 ± 86.1 | 220.1 ± 80.8 | NS | NS | NS |
ALT, U/L | 452.1 ± 175.3 | 488.7 ± 251.4 | 430.6 ± 186.5 | NS | NS | NS |
Hb increase (1d), g/L | 0.5 ± 0.2 | 0.6 ± 0.4 | 2.3 ± 1.0 | NS | <0.05† | <0.05§ |
Hb increase (3d) | 0.6 ± 0.3 | 0.5 ± 0.2 | 2.5 ± 0.8 | NS | <0.05† | <0.05§ |
Hospital stay, d | 8.4 ± 2.2 | 6.7 ± 2.8 | 5.4 ± 1.3 | <0.05* | <0.05† | <0.05§ |
Hospitalization expenses, RMB (thousand) | 66.5 ± 21.5 | 53.5 ± 16.8 | 41.2 ± 13.6 | <0.05* | <0.05† | <0.05§ |
Haemoglobin = Hb; Hb increase = Hb (postoperaion) - Hb (preoperation); F = female; M = male; TBil = Total bilirubin; IBil = Indirect bilirubin; AST = glutamic oxalacetic transaminase; ALT = glutamic-pyruvic transaminase; NS = not significant.
Pα FT group comparring to RT group, <0.05 has statistical significance*;
PβFT + ISBS group comparring to RT group, <0.05 has statistical significance†;
PγFT + ISBS group comparring to FT group, <0.05 has statistical significance§.